Latest Insider Transactions at Aquestive Therapeutics, Inc. (AQST)
This section provides a real-time view of insider transactions for Aquestive Therapeutics, Inc. (AQST). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Aquestive Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Aquestive Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 26
2024
|
Cassie Jung Chief Operating Officer |
SELL
Open market or private sale
|
Indirect |
44
-100.0%
|
$176
$4.87 P/Share
|
|
Aug 09
2024
|
Carl N Kraus Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,819
-4.12%
|
$32,457
$3.43 P/Share
|
|
Jun 07
2024
|
Sherry Korczynski SVP Sales and Marketing |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
May 10
2024
|
Stephen Wargacki Chief Science Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+3.6%
|
-
|
|
Mar 15
2024
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
SELL
Open market or private sale
|
Direct |
50,000
-4.83%
|
$300,000
$6.0 P/Share
|
|
Mar 10
2024
|
Cassie Jung Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,132
-0.47%
|
$4,528
$4.88 P/Share
|
|
Mar 10
2024
|
Stephen Wargacki Chief Science Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,687
-0.65%
|
$6,748
$4.88 P/Share
|
|
Mar 09
2024
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,895
-0.57%
|
$23,580
$4.88 P/Share
|
|
Mar 09
2024
|
Cassie Jung Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,300
-3.36%
|
$33,200
$4.88 P/Share
|
|
Mar 09
2024
|
Stephen Wargacki Chief Science Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,269
-4.16%
|
$45,076
$4.88 P/Share
|
|
Mar 09
2024
|
A Ernest Toth Jr SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,705
-4.5%
|
$46,820
$4.88 P/Share
|
|
Mar 09
2024
|
Lori J Braender SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
10,530
-3.25%
|
$42,120
$4.88 P/Share
|
|
Mar 09
2024
|
Peter E. Boyd See Remark |
SELL
Payment of exercise price or tax liability
|
Direct |
8,370
-3.4%
|
$33,480
$4.88 P/Share
|
|
Mar 09
2024
|
Daniel Barber President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
37,938
-4.3%
|
$151,752
$4.88 P/Share
|
|
Mar 08
2024
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
SELL
Open market or private sale
|
Direct |
25,000
-2.35%
|
$125,000
$5.19 P/Share
|
|
Mar 07
2024
|
Stephen Wargacki Chief Science Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,500
+29.34%
|
-
|
|
Mar 07
2024
|
Peter E. Boyd See Remark |
BUY
Grant, award, or other acquisition
|
Direct |
86,250
+25.96%
|
-
|
|
Mar 07
2024
|
Cassie Jung Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
101,250
+29.06%
|
-
|
|
Mar 07
2024
|
Daniel Barber President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
242,600
+21.55%
|
-
|
|
Mar 07
2024
|
Carl N Kraus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,500
+30.0%
|
-
|
|
Mar 07
2024
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,500
+7.19%
|
-
|
|
Mar 07
2024
|
A Ernest Toth Jr SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+31.58%
|
-
|
|
Mar 07
2024
|
Lori J Braender SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+29.43%
|
-
|
|
Aug 09
2023
|
Carl N Kraus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+50.0%
|
-
|
|
Mar 10
2023
|
Stephen Wargacki Chief Science Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,981
-1.24%
|
$0
$0.79 P/Share
|
|
Mar 10
2023
|
Cassie Jung Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,365
-0.93%
|
-
|
|
Mar 09
2023
|
A Ernest Toth Jr SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
140,000
+50.0%
|
-
|
|
Mar 09
2023
|
Stephen Wargacki Chief Science Officer |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+45.46%
|
-
|
|
Mar 09
2023
|
Lori J Braender SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+44.28%
|
-
|
|
Mar 09
2023
|
Daniel Barber President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
447,000
+41.1%
|
-
|
|
Mar 09
2023
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+9.23%
|
-
|
|
Mar 09
2023
|
Cassie Jung Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
110,000
+42.84%
|
-
|
|
Mar 09
2023
|
Ken W. Marshall SVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+50.0%
|
-
|
|
Mar 09
2023
|
Peter E. Boyd See Remark |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+38.53%
|
-
|
|
Jun 14
2022
|
Peter E. Boyd See Remark |
BUY
Open market or private purchase
|
Direct |
5,000
+7.75%
|
$0
$0.81 P/Share
|
|
Jun 08
2022
|
Lori J Braender SVP, General Counsel |
BUY
Open market or private purchase
|
Direct |
13,761
+26.2%
|
$0
$0.96 P/Share
|
|
Jun 08
2022
|
Peter E. Boyd See Remark |
BUY
Open market or private purchase
|
Direct |
2,293
+4.04%
|
$0
$0.96 P/Share
|
|
Jun 08
2022
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
BUY
Open market or private purchase
|
Direct |
45,871
+4.94%
|
$0
$0.96 P/Share
|
|
Jun 08
2022
|
Daniel Barber President and CEO |
BUY
Open market or private purchase
|
Direct |
91,743
+32.14%
|
$0
$0.96 P/Share
|
|
Aug 26
2021
|
Keith J Kendall CEO and President |
BUY
Bona fide gift
|
Indirect |
1,000
+50.0%
|
-
|
|
Aug 26
2021
|
Keith J Kendall CEO and President |
SELL
Bona fide gift
|
Direct |
1,000
-0.16%
|
-
|
|
May 10
2021
|
John Cochran |
SELL
Bona fide gift
|
Direct |
37,500
-27.38%
|
-
|
|
Mar 12
2021
|
John Cochran |
BUY
Other acquisition or disposition
|
Direct |
61,901
+11.84%
|
-
|
|
Mar 12
2021
|
Douglas K Bratton |
BUY
Other acquisition or disposition
|
Indirect |
1,783,578
+47.79%
|
-
|
|
Mar 12
2021
|
Douglas K Bratton |
SELL
Other acquisition or disposition
|
Indirect |
3,475,914
-37.49%
|
-
|
|
Mar 09
2021
|
Douglas K Bratton |
SELL
Bona fide gift
|
Direct |
62,500
-83.24%
|
-
|
|
Feb 10
2021
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
SELL
Open market or private sale
|
Direct |
23,460
-2.73%
|
$140,760
$6.75 P/Share
|
|
Feb 09
2021
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
SELL
Open market or private sale
|
Direct |
11,540
-1.32%
|
$69,240
$6.75 P/Share
|
|
Feb 08
2021
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
SELL
Open market or private sale
|
Direct |
40,792
-4.47%
|
$244,752
$6.5 P/Share
|
|
Dec 30
2020
|
Keith J Kendall CEO and President |
BUY
Bona fide gift
|
Indirect |
2,000
+50.0%
|
-
|